应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CRNX Crinetics Pharmaceuticals Inc.
停牌 09-11 16:00:00 EDT
84.95
+0.00
0.00%
最高
84.95
最低
84.95
成交量
0.00
今开
84.95
昨收
84.95
日振幅
0.00%
总市值
90.13亿
流通市值
81.15亿
总股本
1.06亿
成交额
0.00
换手率
0.00%
流通股本
9,553万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
高盛9月“确信名单”更新:美股纳入福泰制药 欧股力推莱茵、Adyen和塔兰克斯
智通财经 · 09-02
高盛9月“确信名单”更新:美股纳入福泰制药 欧股力推莱茵、Adyen和塔兰克斯
Crinetics Pharmaceuticals 宣布:不再提供业绩指引,撤回此前发布的预测
美股速递 · 08-04
Crinetics Pharmaceuticals 宣布:不再提供业绩指引,撤回此前发布的预测
财报前瞻|Crinetics Pharmaceuticals Inc.本季度营收预计翻倍增长,机构观点偏积极
财报Agent · 07-29
财报前瞻|Crinetics Pharmaceuticals Inc.本季度营收预计翻倍增长,机构观点偏积极
财报前瞻|Crinetics Pharmaceuticals Inc.机构偏谨慎
财报Agent · 07-28
财报前瞻|Crinetics Pharmaceuticals Inc.机构偏谨慎
Vertex(VRTX)百亿美元收购罕见病药企 拓宽内分泌管线布局
金吾财讯 · 07-13
Vertex(VRTX)百亿美元收购罕见病药企 拓宽内分泌管线布局
暴涨近99%!Crinetics获福泰制药拟100亿美元现金收购
老虎资讯综合 · 07-07
暴涨近99%!Crinetics获福泰制药拟100亿美元现金收购
异动解读|Crinetics Pharmaceuticals盘中上涨98.85%,福泰制药拟斥资100亿美元溢价收购
行情直击 · 07-07
异动解读|Crinetics Pharmaceuticals盘中上涨98.85%,福泰制药拟斥资100亿美元溢价收购
Piper Sandler下调Crinetics评级至中性,目标价降至85美元
美股速递 · 07-07
Piper Sandler下调Crinetics评级至中性,目标价降至85美元
盘前异动 | 存储股集体回调,美光科技、西部数据跌近5%,中概股多数走低
老虎资讯综合 · 07-07
盘前异动 | 存储股集体回调,美光科技、西部数据跌近5%,中概股多数走低
100亿美元砸出史上最大收购:福泰制药(VRTX.US)溢价100%收购Crinetics(CRNX.US),杀入内分泌赛道
智通财经 · 07-07
100亿美元砸出史上最大收购:福泰制药(VRTX.US)溢价100%收购Crinetics(CRNX.US),杀入内分泌赛道
美股夜盘|存储概念股普跌,美光科技、闪迪跌超2%;Crinetics涨超100%、费哲金融服务涨6%、Rivian跌近9%
美股夜盘 · 07-07
美股夜盘|存储概念股普跌,美光科技、闪迪跌超2%;Crinetics涨超100%、费哲金融服务涨6%、Rivian跌近9%
福泰制药拟斥资100亿美元收购Crinetics制药公司
老虎资讯综合 · 07-07
福泰制药拟斥资100亿美元收购Crinetics制药公司
SEC文件披露:特定情况下交易终止,Crinetics Pharmaceuticals或需向福泰制药支付3.5047亿美元解约费
美股速递 · 07-07
SEC文件披露:特定情况下交易终止,Crinetics Pharmaceuticals或需向福泰制药支付3.5047亿美元解约费
Crinetics与福泰制药交易预计2029年提升后者非GAAP运营收入
美股速递 · 07-07
Crinetics与福泰制药交易预计2029年提升后者非GAAP运营收入
Crinetics Pharmaceuticals:融资获美国银行与摩根士丹利的45亿美元全额承诺过桥贷款支持
美股速递 · 07-07
Crinetics Pharmaceuticals:融资获美国银行与摩根士丹利的45亿美元全额承诺过桥贷款支持
Crinetics公布Atumelnant治疗先天性肾上腺皮质增生症二期试验完整结果,并于Endo 2026进行口头报告
美股速递 · 06-15
Crinetics公布Atumelnant治疗先天性肾上腺皮质增生症二期试验完整结果,并于Endo 2026进行口头报告
Crinetics Pharmaceuticals Inc. 预期2026年GAAP运营支出6-6.5亿美元;非GAAP运营支出4.8-5.2亿美元
美股速递 · 05-08
Crinetics Pharmaceuticals Inc. 预期2026年GAAP运营支出6-6.5亿美元;非GAAP运营支出4.8-5.2亿美元
Crinetics Pharmaceuticals, Inc.2024财年实现净利润-2.98亿美元,同比减少38.60%
市场透视 · 2025-03-08
Crinetics Pharmaceuticals, Inc.2024财年实现净利润-2.98亿美元,同比减少38.60%
Citizens Capital Markets:维持Crinetics Pharmaceuticals(CRNX.US)评级,由优于大市调整至优于大市评级, 目标价由92.00美元调整至91.00美元。
金融界 · 2025-02-28
Citizens Capital Markets:维持Crinetics Pharmaceuticals(CRNX.US)评级,由优于大市调整至优于大市评级, 目标价由92.00美元调整至91.00美元。
异动解读 | Crinetics制药盘中大涨5.09%,公司上一季度亏损收窄
异动解读 · 2025-02-28
异动解读 | Crinetics制药盘中大涨5.09%,公司上一季度亏损收窄
加载更多
公司概况
公司名称:
Crinetics Pharmaceuticals Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Crinetics Pharmaceuticals, Inc.于2008年11月18日根据特拉华州法律注册成立。该公司是一家临床阶段制药公司,致力于发现,开发和商业化用于治疗罕见内分泌疾病和内分泌相关肿瘤的新药。 内分泌途径的功能是保持体内平衡,并且通常使用通过G蛋白偶联受体或GPCRs起作用的肽激素来调节生理学的许多方面,包括生长,能量,代谢,胃肠功能和应激反应。
发行价格:
--
{"stockData":{"symbol":"CRNX","market":"US","secType":"STK","nameCN":"Crinetics Pharmaceuticals Inc.","latestPrice":84.95,"timestamp":1789156800000,"preClose":84.95,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":95530500,"shares":106095205,"eps":-5.029038,"marketStatus":"停牌","change":0,"latestTime":"09-11 16:00:00 EDT","open":84.95,"high":84.95,"low":84.95,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.029038,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1531886400000,"exchange":"NASDAQ","adjPreClose":84.95,"volumeRatio":0},"requestUrl":"/m/hq/s/CRNX","defaultTab":"news","newsList":[{"id":"2664891705","title":"高盛9月“确信名单”更新:美股纳入福泰制药 欧股力推莱茵、Adyen和塔兰克斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891705","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664891705?lang=zh_cn&edition=full","pubTime":"2026-09-02 15:20","pubTimestamp":1788333621,"startTime":"0","endTime":"0","summary":"进入秋季,高盛对其美国及欧洲市场的“确信名单”进行了更新,为投资者指明当前最看好的股票方向。本次调整中,美国名单新增一只大型生物科技股,欧洲名单则迎来三家新面孔。美国名单:新增福泰制药,移除盈透证券在美国市场,高盛将 $福泰制药$纳入确信名单,同时移除了 $盈透证券$,调整后名单保留23只股票。高盛还表示,塔兰克斯的国际零售业务是被低估的增长引擎。","market":"us","thumbnail":"https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490866.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["DAL","IBB","EL","MSFL","LU2471134879.HKD","MSFX","MSFW","LU2471134523.USD","MSFU","WFC","MSFT","LU2456880835.USD","IE00BFTCPJ56.SGD","SG9999001176.USD","IDNA","LU1069344957.HKD","MSFO","LU0889565916.HKD","XYZY","UNHG","CRNX","IE00BJT1NW94.SGD","BK4504","GNMX","BK4585","VRTX","XYZG","IE0002270589.USD","IBBQ","IE00B2B36J28.USD","LU1868836757.USD","LU0432979614.USD","LU2237443549.SGD","BIB","LU2471134796.USD","UNH","UNHU","GSX","IBKR","BK4567","BK4532","LU1585245621.USD","MSFY","COP","XYZ","IE0004091025.USD","MSFC","IE00BFXG1179.USD","LU2362541273.HKD","UNHW","LU2265009873.SGD","VXUS","IE00B19Z3581.USD","VGK","TBXU","BK4533","LU0345770993.USD","LU2468319806.SGD","LU2236285917.USD","SG9999001176.SGD","MSFD","UN","IE0034235188.USD","IEV","LU0109394709.USD","LU1868837136.USD","LU2417539215.USD","LU2471134952.CNY","LU1868837300.USD","LU2750360641.GBP","PBE","LU0106831901.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129072760","title":"Crinetics Pharmaceuticals 宣布:不再提供业绩指引,撤回此前发布的预测","url":"https://stock-news.laohu8.com/highlight/detail?id=1129072760","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129072760?lang=zh_cn&edition=full","pubTime":"2026-08-04 04:25","pubTimestamp":1785788708,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.(股票代码:CRNX)于今日发布重要声明,明确表示将不再提供任何更新的业绩指引。与此同时,该公司还宣布,其此前出台的财务预测与指导方针将被正式撤回。这一决策意味着,市场将无法再依据既有数据来评估其未来表现,投资者需自行调整预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189313061","title":"财报前瞻|Crinetics Pharmaceuticals Inc.本季度营收预计翻倍增长,机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1189313061","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189313061?lang=zh_cn&edition=full","pubTime":"2026-07-29 00:25","pubTimestamp":1785255911,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.将于2026年08月04日发布财报,市场聚焦新药商业化进展与费用节奏对利润的影响。一致预期显示,本季度公司营收预计为1,484.01万美元,同比增长113.89%;调整后每股收益预计为-1.21美元,同比改善10.07%;息税前利润预计为-1.36亿美元,同比改善20.45%。由于预测未给出毛利率与净利润或净利率的具体值,相关指标不予展示。产品板块在上季度占比达到96.01%,预计本季度营收增长的主要驱动力仍来自产品收入的放量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|Crinetics Pharmaceuticals Inc.本季度营收预计翻倍增长,机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116538455","title":"财报前瞻|Crinetics Pharmaceuticals Inc.机构偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1116538455","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116538455?lang=zh_cn&edition=full","pubTime":"2026-07-28 11:30","pubTimestamp":1785209438,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.将于2026年08月04日美股盘后发布财报,市场聚焦核心管线商业化放量与收购进展对费用和盈利路径的影响。公司收入结构以产品销售为主,上季度“产品”收入为1,030.60万美元,占比96.01%,显示核心商业化产品对现金流与规模化收入的带动作用。发展前景中体量最大的现有业务仍来自核心口服内分泌产品条线,上季度相关产品收入1,030.60万美元,在带动公司整体营收同比+2873.41%中贡献最为明显。从近期覆盖机构的表态看,偏谨慎的观点占优。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651117599","title":"Vertex(VRTX)百亿美元收购罕见病药企 拓宽内分泌管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2651117599","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651117599?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:10","pubTimestamp":1783951848,"startTime":"0","endTime":"0","summary":"金吾财讯 | Vertex Pharmaceuticals 与 Crinetics Pharmaceuticals 共同披露收购协议,企业将以每股 85 美元现金完成标的全额收购,交易对应 Crinetics 整体股权价值约 100 亿美元,扣除标的账面现金后净交易对价 88 亿美元,交易预计 2026 年第三季度完成,消息落地后 Crinetics 盘后股价实现翻倍上涨。Vertex 计划依托自有现金搭配债务工具完成交易资金筹措,美国银行、摩根士丹利提供 45 亿美元全额过渡性融资,收购落地后企业罕见病内分泌赛道产品矩阵将实现大幅扩容。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302497","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","IE00B19Z9Z06.USD","IE00BZ9MQY76.HKD","LU2456880835.USD","LU0566484027.USD","LU1069344957.HKD","IE0002141913.USD","LU1778281490.HKD","LU0109394709.USD","LU0061475181.USD","PBE","LU2362541273.HKD","BK4588","LU0757428866.USD","LU0079474960.USD","IBB","LU2362541513.USD","LU2417539215.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2462157665.USD","BIB","SG9999001176.SGD","BK4585","CRNX","IE00BJT1NW94.SGD","BK4532","VERX","LU1093756325.SGD","IE00B2B36J28.USD","LU0432979614.USD","IE0002270589.USD","LU0889565916.HKD","LU1674673428.USD","IE00B19Z3581.USD","IE00B894F039.SGD","LU0256863811.USD","LU2362540622.SGD","IBBQ","IDNA","SG9999013999.USD","SG9999001176.USD","VRTX","LU1093756168.USD","BK4007","LU2237438978.USD","LU0234570918.USD","LU1585245621.USD","IE00B4R5TH58.HKD","LU1035775433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161465425","title":"暴涨近99%!Crinetics获福泰制药拟100亿美元现金收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1161465425","media":"老虎资讯综合","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161465425?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:52","pubTimestamp":1783432357,"startTime":"0","endTime":"0","summary":"7月7日,Crinetics美股盘中大幅上涨,涨近99%。消息面上,福泰制药同意以约100亿美元现金收购Crinetics,每股收购价为85美元,较Crinetics周一收盘价溢价约102%。受交易影响,福泰制药股价跌超2%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/ce70f982c0b1f1a2ba3407f02bcf893f","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/ce70f982c0b1f1a2ba3407f02bcf893f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187410524","title":"异动解读|Crinetics Pharmaceuticals盘中上涨98.85%,福泰制药拟斥资100亿美元溢价收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1187410524","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187410524?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:35","pubTimestamp":1783431342,"startTime":"0","endTime":"0","summary":"7月7日,Crinetics Pharmaceuticals盘中上涨98.85%,报83.5美元/股,成交额28.32亿美元。消息面上,福泰制药宣布将以每股85美元现金收购Crinetics,交易总股权价值约100亿美元,较收购前股价溢价近100%。福泰制药预计此次收购将为其带来约50亿美元峰值销售机会,并于2029年对非GAAP运营收入产生积极贡献。收购消息公布后,Piper Sandler及Cantor Fitzgerald均将Crinetics评级下调至中性,目标价调整至85美元,与收购报价一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1156298608","title":"Piper Sandler下调Crinetics评级至中性,目标价降至85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156298608","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156298608?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:27","pubTimestamp":1783427261,"startTime":"0","endTime":"0","summary":"投资机构Piper Sandler调整了对Crinetics Pharmaceuticals Inc. (CRNX) 的投资评级,将其从“增持”下调至“中性”。与此同时,该机构也大幅调降了该公司的目标股价,从原先的97美元降至85美元。这一调整反映了分析师对该公司近期前景的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134104489","title":"盘前异动 | 存储股集体回调,美光科技、西部数据跌近5%,中概股多数走低","url":"https://stock-news.laohu8.com/highlight/detail?id=1134104489","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134104489?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:02","pubTimestamp":1783411365,"startTime":"0","endTime":"0","summary":"7月7日,美股三大股指期货盘前表现分化,道指期货升近0.2%,标普500指数期货跌近0.2%,纳指期货跌超0.8%。盘面上,大型科技股小幅上涨,微软涨超0.6%,亚马逊、Meta小幅走高;存储概念股盘前集体下跌,美光科技、西部数据跌近5%,闪迪跌超4%,希捷科技跌超3%;热门中概股多数走低,京东、拼多多跌近1%,百度跌近2%。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e2482c489456454bb2227ec34bbeb7d8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDQ","METU","AZYY","FBYY","METD","NVDS","SNDC","MUD","MULL","SNDU","BABW","KPDD","INTC","MSFT","NVDD","NVDY","MSFL","LINT","MSFX","AAPB","AMDW","NVD","NVDG","WDC","JD","MSFU","SNDK","NVDO","AAPY","ANV","AMZD","NVII","BIDU","MVLL","BBYY","NVDB","NVDU","BABO","AMYY","NVDW","KJD","FBL","FBY","AMUU","AMZZ","NVDL","MU","INTW","SNDQ","APLY","BIDG","MSFW","MSFY","AAPL","META","AMD","PDD","BABA","MUU","MRVU","NTES","CRNX","KBAB","AMDU","07388","AMDG","AAPU","SNDG","MRVL","NVDX","AMDD","MSFD","SNXX","STX","NVYY","BABX","WDCX","DAMD","AMZU","07788","AMDL","AAPX","METW","BABU","KBDU","AMZP","AMZW","DIPS","NVDA","MSFO","AMDY","PDDL","AAPD","AMZN","AMZY","AAPW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649708736","title":"100亿美元砸出史上最大收购:福泰制药(VRTX.US)溢价100%收购Crinetics(CRNX.US),杀入内分泌赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2649708736","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649708736?lang=zh_cn&edition=full","pubTime":"2026-07-07 08:35","pubTimestamp":1783384535,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765992.SGD","LU0417517546.SGD","BK4533","LU0256863811.USD","LU0889565916.HKD","LU0234570918.USD","LU1093756168.USD","SGXZ57979304.SGD","IE00B19Z9Z06.USD","IBB","BK4585","LU1035775433.USD","LU2417539215.USD","PBE","LU0079474960.USD","LU0109394709.USD","BK4139","LU1093756325.SGD","LU2456880835.USD","IE0002270589.USD","SG9999001176.SGD","IE00BJT1NW94.SGD","LU1585245621.USD","LU1778281490.HKD","IE00BZ9MQY76.HKD","LU2237438978.USD","IE00B4R5TH58.HKD","IBBQ","LU2362541273.HKD","LU0432979614.USD","LU1430594728.SGD","BIB","LU0823416689.USD","IDNA","VRTX","CRNX","LU2324357040.USD","BBH","IE00B19Z3581.USD","LU2362540622.SGD","BK4007","LU0061475181.USD","SG9999001176.USD","IE00B19Z9P08.USD","IE00B2B36J28.USD","LU0289739699.SGD","LU1674673691.USD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188431917","title":"美股夜盘|存储概念股普跌,美光科技、闪迪跌超2%;Crinetics涨超100%、费哲金融服务涨6%、Rivian跌近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188431917","media":"美股夜盘","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188431917?lang=zh_cn&edition=full","pubTime":"2026-07-07 08:06","pubTimestamp":1783382813,"startTime":"0","endTime":"0","summary":"费哲金融服务涨6.2%,《华尔街日报》称多家大型银行探讨收购其旗下支付网络,或为绕开借记卡手续费上限。SpaceX跌1.75%,社交媒体讨论称其股票面临破发压力。Rivian Automotive, Inc. 跌8.99%,宣布增发7500万股以履行美国能源部贷款相关出资,并公布二季度营收预期,且拟授予承销商30天超额配售权,稀释担忧压制股价。存储芯片股下跌,Roundhill Memory ETF跌2.75%,闪迪跌2.55%,美光科技跌2.31%,西部数据跌1.93%,希捷科技跌1.18%。其中,美光科技受高管减持消息影响。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e2482c489456454bb2227ec34bbeb7d8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOXQ","LU0354030438.USD","SCHM","FAI","LU1201861165.SGD","IDRV","LU0963586101.USD","OPTZ","SNDG","MUU","LU1861217088.USD","BK4553","IE0002270589.USD","AIQ","LU2168564149.EUR","FSMD","BK4141","LU2125909916.SGD","CRNX","LU2211815571.USD","LU2357627491.SGD","LU0238689110.USD","BK4512","LU0683600562.USD","IE00B5949003.HKD","SG9999001424.SGD","LU2458330243.SGD","EFIV","LU1868837300.USD","LU2168564495.EUR","PTF","LU1323610961.USD","MUD","LU0127658192.USD","LU1861220033.SGD","LU0054578231.USD","WUGI","GB00BDT5M118.USD","LU1868836757.USD","LU2750360997.AUD","FDRV","XNTK","IE00BK4W5M84.HKD","LU2360107168.USD","IE00BWXC8680.SGD","LU0642271901.SGD","LU0157215616.USD","LU0859254822.USD","IE00BK4W5L77.USD","PSI","VGT","LU2471134523.USD","CNAV","IE0034235303.USD","IETC","LU2250418816.HKD","IXN","LU1823568750.SGD","IE00B7SZLL34.SGD","SNDC","LU0274383776.USD","LEGR","LU0096364046.USD","IE00BKDWB100.SGD","LU1316542783.SGD","LU0889565833.HKD","BK4596","LU0070302665.USD","BK4532","LU1923622291.USD","WLDR","BK4555","LU1267930813.SGD","LU2089985449.USD","RAM","IE00B1XK9C88.USD","JGRO","LU2048586759.USD","FISV","QQQG","EMSF","IE00BJLML261.HKD","LU0719512351.SGD","LU0130103400.USD","SMH","IE00B19Z3581.USD","FTEC","LU0082616367.USD","LU0787776722.HKD","EGGY","LU0081259029.USD","BK4227","AIFD","FXL","LU1803068979.SGD","SNXX","BK4585","XLK","LU2471134952.CNY","LU2471134796.USD","MULL","BK4543","LU1201861249.SGD","LU0130102774.USD","COWG","LU0320765489.SGD","FDTX","RULE","LU2168564065.EUR","SHOC","IE0009356076.USD","BK4099","LU2543165471.USD","ARTY","LU1868836914.USD","CGGO","LU2458330169.SGD","BK4566","DRAL","SNDQ","BK4533","BK4605","LU1366333091.USD","LU1852331112.SGD","LU1861215975.USD","LU2125909759.SGD","BK4170","LU2168563687.JPY","LU2471134879.HKD","FINX","SCHA","IE000M9KFDE8.USD","USXF","TMSL","LU0203345920.USD","LU0792757196.USD","LU2168564222.USD","LU1914381329.SGD","LU2360106780.USD","LU0980610538.SGD","LU1868837136.USD","DRAM","LU2931357623.SGD","CHPS","SNDK","SOXX","LU1861220207.SGD","BK4106","LU1046421795.USD","SNDU","RVNL","LU0203347892.USD","LU2102340556.USD","LU0648000940.SGD","BK4575","TRFK","BAI","BK4579","LU2290526834.HKD","LU1989764748.USD","LU0208291251.USD","BK4554","LU1989764664.SGD","BK4527","LU0648001328.SGD","LU0889566641.SGD","FCUS","CHAT","LU2054465674.USD","LU0056508442.USD","IE00B19Z3B42.SGD","FTXL","BK4547","RIVN","LU2286300806.USD","MU","LU2750360641.GBP","AIS","LU0154236417.USD","LU1868836591.USD","LU0109392836.USD","LU0354030511.USD","LU0061475181.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1198601451","title":"福泰制药拟斥资100亿美元收购Crinetics制药公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1198601451","media":"老虎资讯综合","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198601451?lang=zh_cn&edition=full","pubTime":"2026-07-07 06:13","pubTimestamp":1783376037,"startTime":"0","endTime":"0","summary":"7月7日,Vertex制药公司周一宣布,将以每股$85.00的现金价格收购Crinetics制药公司,交易总股权价值约为100亿美元,扣除预计所获现金后净值约为88亿美元。消息公布后,Crinetics盘后股价飙升近100%。两家公司董事会均已一致批准此次交易。交易预计于2026年第三季度完成,尚需满足惯常交割条件,包括获得监管机构批准及Crinetics股东批准。Crinetics旗下产品PALSONIFY已于2025年9月获得美国食品药品监督管理局批准,近期亦获欧洲药品管理局批准上市。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"福泰制药拟斥资100亿美元收购Crinetics制药公司","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159544198","title":"SEC文件披露:特定情况下交易终止,Crinetics Pharmaceuticals或需向福泰制药支付3.5047亿美元解约费","url":"https://stock-news.laohu8.com/highlight/detail?id=1159544198","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159544198?lang=zh_cn&edition=full","pubTime":"2026-07-07 05:22","pubTimestamp":1783372928,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件披露,Crinetics Pharmaceuticals Inc. 与福泰制药之间的交易若在特定情况下被终止,前者可能需要向后者支付高达3.5047亿美元的终止费用。该文件明确了触发这一巨额财务义务的具体情形。协议条款显示,这笔费用的支付并非自动生效,而是与特定的终止条件紧密挂钩。然而,这也同时意味着,一旦协议因规定情形破裂,Crinetics Pharmaceuticals将面临显著的财务支出。目前,市场正密切关注两家公司后续的动向以及该交易的具体进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU0058720904.USD","LU0320765992.SGD","CRNX","LU2324357040.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IBB","LU0079474960.USD","LU0289739699.SGD","LU2417539215.USD","SG9999001176.SGD","IBBQ","BBH","LU0256863811.USD","BK4588","IE00B2B36J28.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00BZ9MQY76.HKD","LU1674673428.USD","BK4567","LU1674673691.USD","LU0823416689.USD","LU1035775433.USD","SG9999001176.USD","SGXZ57979304.SGD","LU0432979614.USD","IDNA","VRTX","IE0002270589.USD","LU1778281490.HKD","LU1069344957.HKD","LU0417517546.SGD","SG9999013999.USD","IE00B19Z3581.USD","LU0109394709.USD","LU2236285917.USD","IE0009355771.USD","LU0234570918.USD","IE00BFTCPJ56.SGD","IE00B19Z9P08.USD","LU1430594728.SGD","BIB","IE00B894F039.SGD","LU2362541513.USD","LU2362541273.HKD","LU2456880835.USD","LU2462157665.USD","BK4585","LU1585245621.USD","IE00B4R5TH58.HKD","LU1093756325.SGD","LU2237438978.USD","PBE","BK4532","BK4139","BK4007","IE00B19Z3B42.SGD","IE00B19Z9Z06.USD","LU2362540622.SGD","BK4533","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127833937","title":"Crinetics与福泰制药交易预计2029年提升后者非GAAP运营收入","url":"https://stock-news.laohu8.com/highlight/detail?id=1127833937","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127833937?lang=zh_cn&edition=full","pubTime":"2026-07-07 04:07","pubTimestamp":1783368452,"startTime":"0","endTime":"0","summary":"根据最新披露的财务预测,Crinetics Pharmaceuticals Inc. 与福泰制药达成的战略合作,预计将在2029年对福泰制药的非通用会计准则运营收入产生积极贡献。\n此次交易的结构设计旨在通过长期协同效应,增强福泰制药的盈利质量。分析指出,该合作不仅将拓展福泰制药在特定治疗领域的产品管线,还可能优化其整体运营效率。市场预期,随着合作项目进入成熟阶段,其对财务指标的正面影响将逐步显现。\n财务模型显示,此次合作带来的收入增长与成本协同效应,是推动非通用会计准则运营收入提升的关键因素。投资者正密切关注交易细节及后续整合进程,以评估其长期价值创造潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1778281490.HKD","IE00B894F039.SGD","LU2236285917.USD","LU2237438978.USD","LU0058720904.USD","BK4139","IE0009355771.USD","IDNA","LU0823416689.USD","BK4007","IE00B19Z9P08.USD","LU2456880835.USD","IBB","BK4532","LU2462157665.USD","IE0002270589.USD","SGXZ57979304.SGD","LU1674673691.USD","VRTX","LU0889565916.HKD","LU0234570918.USD","IE00BJT1NW94.SGD","LU0079474960.USD","LU0256863811.USD","LU0289739699.SGD","LU0417517546.SGD","IE00B19Z3B42.SGD","LU1093756325.SGD","LU1585245621.USD","PBE","LU2362541513.USD","LU2362541273.HKD","SG9999001176.USD","BK4567","IE00B4R5TH58.HKD","IE00BZ9MQY76.HKD","IBBQ","LU0061475181.USD","BK4588","IE00B19Z9Z06.USD","IE00BJJMRZ35.SGD","BBH","LU2362540622.SGD","IE0002141913.USD","CRNX","IE00B19Z3581.USD","BK4585","LU1093756168.USD","IE00BFTCPJ56.SGD","LU1069344957.HKD","SG9999013999.USD","BK4533","IE00B2B36J28.USD","LU0432979614.USD","LU1035775433.USD","SG9999001176.SGD","LU2417539215.USD","LU0320765992.SGD","LU2324357040.USD","LU1430594728.SGD","BIB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179291339","title":"Crinetics Pharmaceuticals:融资获美国银行与摩根士丹利的45亿美元全额承诺过桥贷款支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1179291339","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179291339?lang=zh_cn&edition=full","pubTime":"2026-07-07 04:06","pubTimestamp":1783368378,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. 的融资计划,已获得来自美国银行和摩根士丹利高级融资部门提供的总额高达45亿美元的全额承诺过桥贷款支持。这笔资金将为公司的战略推进提供坚实的财务后盾。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU1069344957.HKD","LU2456880835.USD","SGXZ57979304.SGD","LU1778281490.HKD","IE00B894F039.SGD","VRTX","IE00BZ9MQY76.HKD","LU0058720904.USD","IE00B19Z3B42.SGD","IE0002270589.USD","CRNX","IE00B19Z9Z06.USD","LU0061475181.USD","LU1093756325.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B19Z9P08.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","IE0009355771.USD","LU0432979614.USD","LU0417517546.SGD","IDNA","LU0889565916.HKD","LU2236285917.USD","LU2237438978.USD","LU2362541513.USD","IBBQ","LU2324357040.USD","LU0289739699.SGD","BK4588","BK4585","LU1035775433.USD","LU1674673691.USD","LU2362541273.HKD","BK4007","LU1093756168.USD","LU1674673428.USD","BIB","BBH","IBB","IE00B19Z3581.USD","LU0320765992.SGD","BK4139","SG9999001176.USD","LU2362540622.SGD","LU1430594728.SGD","IE00B2B36J28.USD","BK4532","LU0109394709.USD","SG9999001176.SGD","SG9999013999.USD","LU0823416689.USD","LU1585245621.USD","IE00B4R5TH58.HKD","BK4567","BK4533","LU2417539215.USD","LU2462157665.USD","LU0256863811.USD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117418128","title":"Crinetics公布Atumelnant治疗先天性肾上腺皮质增生症二期试验完整结果,并于Endo 2026进行口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1117418128","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117418128?lang=zh_cn&edition=full","pubTime":"2026-06-15 04:30","pubTimestamp":1781469015,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. 在Endo 2026会议上,以口头报告形式公布了其药物Atumelnant用于治疗先天性肾上腺皮质增生症的二期临床试验完整数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101516072","title":"Crinetics Pharmaceuticals Inc. 预期2026年GAAP运营支出6-6.5亿美元;非GAAP运营支出4.8-5.2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101516072","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101516072?lang=zh_cn&edition=full","pubTime":"2026-05-08 04:29","pubTimestamp":1778185754,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. 公布了其2026财年的财务指引。该公司预计,按照美国通用会计准则(GAAP)计算,其2026年的运营支出将在6亿美元至6.5亿美元之间。同时,根据非美国通用会计准则(Non-GAAP)测算,公司预期的运营支出范围则为4.8亿美元至5.2亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517589074","title":"Crinetics Pharmaceuticals, Inc.2024财年实现净利润-2.98亿美元,同比减少38.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517589074","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517589074?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363257,"startTime":"0","endTime":"0","summary":"3月8日,Crinetics Pharmaceuticals, Inc.公布财报,公告显示公司2024财年净利润为-2.98亿美元,同比减少38.60%;其中营业收入为1.04百万美元,同比减少74.06%,每股基本收益为-3.69美元。从资产负债表来看,Crinetics Pharmaceuticals, Inc.总负债4.01亿美元,其中短期债务7.15百万美元,资产负债比为4.31,流动比率为0.24。机构评级:截至2025年3月8日,当前有14家机构对Crinetics Pharmaceuticals, Inc.目标价做出预测,其中目标均价为75.64美元,其中最低目标价为55.00美元,最高目标价为100.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000248abed66f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000248abed66f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514904376","title":"Citizens Capital Markets:维持Crinetics Pharmaceuticals(CRNX.US)评级,由优于大市调整至优于大市评级, 目标价由92.00美元调整至91.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514904376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514904376?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:41","pubTimestamp":1740757319,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets:维持Crinetics Pharmaceuticals(CRNX.US)评级,由优于大市调整至优于大市评级, 目标价由92.00美元调整至91.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28234148468148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171905954","title":"异动解读 | Crinetics制药盘中大涨5.09%,公司上一季度亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1171905954","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171905954?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:22","pubTimestamp":1740756147,"startTime":"0","endTime":"0","summary":"Crinetics制药公司今日盘中大涨5.09%,引发了市场的广泛关注。\n公司日前公布的最新季度业绩显示,2024年第四季度,公司调整后每股亏损为88美分,同比收窄2美分,略好于分析师预期的89美分亏损。尽管如此,公司当季实际亏损8060万美元,同比加大。\n不过,公司当季度业绩整体表现略好于预期,以及分析师看好其长期前景,推动了公司股价今日盘中出现较大涨幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Crinetics制药盘中大涨5.09%,公司上一季度亏损收窄","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crinetics.com;ir.crinetics.com;investors.vrtx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0058},{"period":"3month","weight":1.4645},{"period":"6month","weight":1.2659},{"period":"1year","weight":1.5185},{"period":"ytd","weight":0.8249}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Crinetics Pharmaceuticals, Inc.于2008年11月18日根据特拉华州法律注册成立。该公司是一家临床阶段制药公司,致力于发现,开发和商业化用于治疗罕见内分泌疾病和内分泌相关肿瘤的新药。 内分泌途径的功能是保持体内平衡,并且通常使用通过G蛋白偶联受体或GPCRs起作用的肽激素来调节生理学的许多方面,包括生长,能量,代谢,胃肠功能和应激反应。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.078473},{"month":2,"riseRate":0.5,"avgChangeRate":-0.021565},{"month":3,"riseRate":0.25,"avgChangeRate":-0.056934},{"month":4,"riseRate":0.625,"avgChangeRate":0.06869},{"month":5,"riseRate":0.5,"avgChangeRate":-0.026047},{"month":6,"riseRate":0.625,"avgChangeRate":0.005036},{"month":7,"riseRate":0.5,"avgChangeRate":0.131715},{"month":8,"riseRate":0.555556,"avgChangeRate":0.0512},{"month":9,"riseRate":0.333333,"avgChangeRate":0.093181},{"month":10,"riseRate":0.5,"avgChangeRate":0.007484},{"month":11,"riseRate":0.875,"avgChangeRate":0.104868},{"month":12,"riseRate":0.75,"avgChangeRate":0.036899}],"exchange":"NASDAQ","name":"Crinetics Pharmaceuticals Inc.","nameEN":"Crinetics Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Crinetics Pharmaceuticals Inc.(CRNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Crinetics Pharmaceuticals Inc.(CRNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Crinetics Pharmaceuticals Inc.,CRNX,Crinetics Pharmaceuticals Inc.股票,Crinetics Pharmaceuticals Inc.股票老虎,Crinetics Pharmaceuticals Inc.股票老虎国际,Crinetics Pharmaceuticals Inc.行情,Crinetics Pharmaceuticals Inc.股票行情,Crinetics Pharmaceuticals Inc.股价,Crinetics Pharmaceuticals Inc.股市,Crinetics Pharmaceuticals Inc.股票价格,Crinetics Pharmaceuticals Inc.股票交易,Crinetics Pharmaceuticals Inc.股票购买,Crinetics Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Crinetics Pharmaceuticals Inc.(CRNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Crinetics Pharmaceuticals Inc.(CRNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}